Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Subgroup analyses boost masupirdine potential for AD
Post hoc data from a phase II study presented at AAIC 2022 continue to demonstrate the potential of masupirdine (SUVN-502), a selective 5-HT6 receptor antagonist, as a treatment alternative for the management of neuropsychiatric and cognitive symptoms of Alzheimer’s disease (AD).
Subgroup analyses boost masupirdine potential for AD
15 Aug 2022
HCV reinfection highest among people with ongoing injecting drug use
Reinfection with hepatitis C virus (HCV) is low among people receiving opioid agonist therapy (OAT) but appears to be at its peak during the first 24 weeks following treatment completion and among those with ongoing injecting drug use and needle‒syringe sharing, a study has found.
HCV reinfection highest among people with ongoing injecting drug use
14 Aug 2022
Secukinumab 300 mg leads to sustained improvements in PsA symptoms
Treatment with secukinumab 300 mg significantly improves symptoms of biologic-naïve patients with psoriatic arthritis (PsA) compared with placebo, results from the CHOICE study have shown.
Secukinumab 300 mg leads to sustained improvements in PsA symptoms
12 Aug 2022
Another breakthrough for HIV: Fourth patient goes into long-term remission
Hope springs yet again in the field of HIV treatment, as another HIV patient (reportedly the fourth in the world) goes into remission 3 decades following diagnosis. The patient stopped antiretroviral therapy (ART) after receiving allogeneic hematopoietic stem cell transplantation (HCT) of CCR5-Δ32/Δ32 donor cells for acute myelogenous leukaemia (AML).